2Marbeuf Gueye C, Salerno M, Quidu P, et al. Inhibition of the Pglycoprotein- and multidrug resistance protein-mediated efflux of anthracyclines and calceinacetoxymethyl ester by PAK-104P[J]. Eur J Pharmacol, 2000, 391(3): 207-216.
3Motoji T, Motomura S, Wang YH. Multidrug resistance of acute leukemia and a strategy to overcome it[J]. Int J Hematol, 2000, 72(4): 418-424.
4Swannie HC, Kaye SB. Protein kinase C inhibitors[J]. Curr Oncol Rep, 2002, 4(1): 37-46.
5Komuro Y, Udagawa Y, Susumu N, et al. Paclitaxel and SN-38 overcome cisplatin resistance of cell lines by down-regulating the influx and efflux system of clsplatin[J]. Cancer Res, 2001, 92(11): 1242-1250.
6Poirson Biochat F, Concalves RA, Miceoli L, et al. The expression of drug resistance gene products during the progression of human prostate cancer[J]. Clin Cancer Res, 2000, 6(2): 643-653.
7Burg D, Filippov DV, Hermanns R, et al. Peptidomimetic glutathione analogues as novel gammaGT stable GST inhibitors[J]. Bioorg Med Chem, 2002, 10(1): 195-205.
8Mistry P, Stewart AJ, Dangerfield W, et al. In vitro and in vivo characterization of XRl1576, a novel, orally active, dual inhibitor of topoisomerase I and Ⅱ[J]. Anticancer Drugs, 2002, 13(1): 15-28.
9van Hattum AH, Pinedo HM, Schluper HM, et al. New highly lipophilic camptothecin BNP1350 is an effective drug in experimental human cancer[J]. Int J Cancer, 2000, 15, 88(2): 260-266.
10Kobayashi H, Tahemura Y, Miyachi H. Novel approaches to reversing anti-cancer drug resistance using gene-specific therapeutics[J]. Hum Cell, 2001, 14(3): 172-184.
